retatrutide phase 2 diabetes weight loss 2024 trial type 2 Retatrutide, an experimental weight-loss drug Retatrutide, a TRIPLE agonist (GLP1,

Each state decides which drugs are covered by Medicaid

Retatrutide vs tirzepatide data source note: This comparison includes published and publicly released data from Phase 2 and Phase 3 programs, including the NEJM retatrutide Phase 2 paper, Eli Lilly TRIUMPH-4 results, and SURMOUNT-1 tirzepatide results

For patients who have seen life-changing results with Zepbound, losing access can feel like a devastating loss, like losing a lifeline, McGowan said.

Any changes are indirect results of weight loss, metabolic improvements, or medication side effects

Longevity shouldnt be a luxury everyone deserves access to the science of healthy aging

It also does not handle insurance for brand-name medications